ALNY - アルナイラム・ファ―マシュ―ティカルズ （Alnylam Pharmaceuticals Inc.） アルナイラム・ファ―マシュ―ティカルズALNYのチャート
ALNYの企業情報
| symbol | ALNY |
|---|---|
| 会社名 | Alnylam Pharmaceuticals Inc （アルナイラム・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アルナイラム・ファーマシューティカルズ(Alnylam Pharmaceuticals Inc.)はリボ核酸干渉法(RNAi)に基づく治療薬を開発する生物医薬品会社である。同社の「Alnylam 5x15」は遺伝的疾患の治療向けに、リボ核酸干渉法を用いた新規治療薬の開発及び商品化に注力する。同社の臨床または前臨床開発段階の中核プログラムには、トランスサイレチン媒介性アミロイドーシス(ATTR)の治療向けの「ALN-TTR」、血友病の治療向けの「ALN-APC」、重度の高コレステロール血症の治療向けの「ALN-PCS」、不応性貧血の治療向けの「ALN-HPN」、並びにベータサラセミア及び鎌状赤血球貧血症を含む異常ヘモグロビン症の治療向けの「ALN-TMP」が含まれる。パートナーベースのプログラムとしては、同社は呼吸器合胞体ウイルス(RSV)感染症の治療向けの「ALN-RSV01」、肝癌の治療向けの「ALN-VSP」、並びにハンチントン病(HD)の治療向けの「ALN-HTT」を含む臨床または前臨床開発段階のプログラムを3つ有する。 アルナイラム・ファ―マシュ―ティカルズは米国のバイオテクノロジ―企業。2002年の創業以来、一貫してRNAi（各種疾患の原因となるタンパク質を作り出す遺伝子に直接・選択的に作用する特徴を有する）技術を基盤とした医薬品研究開発を行い、RNAi医薬の研究・開発に必要な多くの特許、技術を保持する。本社はマサチュ―セッツ州ケンブリッジ。 Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. |
| 本社所在地 | 300 Third Street Cambridge MA 02142 USA |
| 代表者氏名 | Michael W. Bonney マイケル・W・ボニー |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 617-551-8200 |
| 設立年月日 | 37742 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2004年 |
| 従業員数 | 749人 |
| url | www.alnylam.com |
| nasdaq_url | https://www.nasdaq.com/symbol/alny |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -600.14400 |
| 終値（lastsale） | 83.21 |
| 時価総額（marketcap） | 8376427179.52 |
| 時価総額 | 時価総額（百万ドル） 8222.408 |
| 売上高 | 売上高（百万ドル） 106.82600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6804.742 |
| 当期純利益 | 当期純利益（百万ドル） -570.73800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Alnylam Pharmaceuticals Inc. revenues increased 48% to $51.8M. Net loss before extraordinary items increased 35% to $305.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $40.5M to $87.2M (expense). |
ALNYのテクニカル分析
ALNYのニュース
Huntington''s Disease Treatment Market is expected to grow from USD 365 million in 2022 to USD 1,517 million by 2030 : GreyViews 2023/02/06 21:00:00 Benzinga
Pune India, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle East and Africa. These are the key regions where the huntington''s disease treatment market is operating and is predicted to expand soon. The manufacturers and suppliers involved in the huntington''s disease treatment market are present across various countries in the above-mentioned regions. Get Sample Copy of This Report @ https://greyviews.com/reports/huntingtons-disease-treatment-market/536/request-sample The report provides a detailed understanding of the market segments which have been formed by combining different prospects such as the drug type, treatment, and region. Apart from this, the key driving factors, restraints, potential growth opportunities, and market challenges are also discussed in the below paragraphs. The significant players operating in the global huntington''s disease treatment market are Teva Pharmaceutical Industries, Vertex Pharmaceuticals Incorporated, AmpliPhi Biosciences Corp, Valeant Pharmaceuticals International Inc., Pfizer, Lundbeck, Alnylam Pharmaceuticals, Inc., Prana Biotechnology Ltd., Cortex Pharmaceuticals Inc., GlaxoSmithKline among other.
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results 2023/02/02 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February 23, 2023, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2022 results as well as expectations for the future via conference call on Thursday, February 23, 2023 at 8
ALNY (Alnylam Pharmaceuticals Inc.) has powerful results 2023/01/27 13:08:00 US Post News
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) closed Thursday at $231.59 per share, up from $229.02 a day earlier. While Alnylam Pharmaceuticals Inc. has overperformed by 1.12%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALNY rose by 76.87%, with highs and lows ranging from $242.97 to $117.58, whereas […]
ClearBridge Select Strategy Q4 2022 Portfolio Manager Commentary (undefined:ALNY) 2023/01/22 09:41:00 Seeking Alpha
ClearBridge is a leading global asset manager committed to active management.
Novartis AG – Consensus Indicates Potential 13.1% Upside 2023/01/20 13:57:15 DirectorsTalk
Novartis AG found using ticker (NVS) have now 4 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 107 and 102 with the average target price sitting at 104.25. Given that the stocks previous close was at 92.16 this indicates there is a potential upside of 13.1%. The day 50 moving average is 89.11 and the 200 moving average now moves to 85.3. The company has a market cap of $198,431m. You can visit the company''s website by visiting: https://www.novartis.com [stock_market_widget type="chart" template="basic" color="green" assets="NVS" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $224,462m based on the market concensus. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers.
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022 2022/12/01 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2022 Top Places to Work in the “Largest Employer” category. This marks the second year in a row Alnylam’s takes the top spot in the Largest Employer category (> 1,000 employees). “I’m immensely proud of our team as we reach our eighth consecutive year on Boston Globe’s Top Places to Work,” said Yvonne Greenstreet, MBChB, C
Alnylam Pharmaceuticals Inc. (ALNY) Rises From The Low: Could It Be A Catbird Seat? 2022/11/26 19:00:00 Stocks Register
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) concluded the trading at $212.72 on Friday, November 25, with a rise of 2.03% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $208.49 and 5Y monthly beta was reading 0.55 with its price kept floating in the … Alnylam Pharmaceuticals Inc. (ALNY) Rises From The Low: Could It Be A Catbird Seat? Read More »
Nuveen Asset Management, LLC Buys 1, Sells 4 in 3rd Quarter 2022/11/15 10:00:04 GuruFocus
Related Stocks: ALNY , GOOGL , META , MTCH , MSFT ,
IRA impact: AstraZeneca and Merck CEOs warn of oncology drug development shifts 2022/11/11 18:45:09 Endpoints News
This latest quarterly earnings season for pharma has been a time for companies to vent about President Biden''s new drug price negotiation law, with some companies like Alnylam pointing to orphan drug designation restrictions, and others like Eli Lilly noting the disparities between small and large molecule drugs when it
Alnylam to Webcast Presentations at Upcoming November Investor Conferences 2022/11/09 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 2:05 pm GMT (9:05 am ET) at the Waldorf Hilton in London Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at 1:15 pm ET at the Lotte New York Palace Hotel in New York City Evercore ISI 5th Annual
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary 2022/09/15 22:47:02 Benzinga
Pfizer (NYSE: PFE ) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7 to $46.29 on day volume of 15.14 million shares, closed regular trading session at $45.94. Alnylam (NASDAQ: ALNY) and Regeneron (NASDAQ: REGN) announced preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH). Alnylam shares traded in a range of $202.6 to $210.86 on day volume of 771.5 thousand shares, closed regular trading session at $208.48. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kymera Therapeutics ’ (NASDAQ: KYMR ) product candidate KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL).
Can you still get a good price for Alnylam Pharmaceuticals Inc. (ALNY) Shares at this point? 2022/09/15 14:48:00 US Post News
A share of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) closed at $208.28 per share on Wednesday, up from $206.59 day before. While Alnylam Pharmaceuticals Inc. has overperformed by 0.82%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALNY rose by 10.80%, with highs and lows ranging from $236.80 […]
Alnylam/Regeneron say early-stage data back Phase 2 trial for NASH drug (NASDAQ:REGN) 2022/09/15 11:29:28 Seeking Alpha
Alnylam (ALNY) and Regeneron (REGN) announced Thursday that early Phase 1 data for ALN-HSD, an experimental therapy for liver disease nonalcoholic steatohepatitis ((NASH)), supported…
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers 2022/09/15 11:00:00 Business Wire
CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH). After single-dose evaluation in healthy adult volunteers (Part A), multiple doses of ALN-HSD are being studied in adult patients with NASH